Helixgate https://validator.w3.org/feed/docs/rss2.html Nisa Leung’s Aulis Capital closes $200M debut fund: Venture Report Alethio: A mutation-agnostic approach to essential thrombocythemia With $600M fund, Formation Bio puts a financing twist on hub-and-spoke model Citizen science program helps find exotic ticks Dren Bio raises $350m for dibotatug clinical development Glenmark opens Allentown distribution hub in US Pelthos and Castle Creek plan merger to target skin diseases Inovio’s Voceryq receives FDA accelerated approval for RRP Bavarian Nordic secures four-year UK vaccine supply deal Lonza to acquire five US manufacturing sites from Merck KGaA FDA to review uniQure’s BLA for Huntington’s gene therapy GEBRO and Spektus sign collaboration for ActraFlex STAT+: Pharmalittle: We’re reading about India’s new manufacturing rules, clinical trials in China, and more Revealing the Chemistry Around Us Through Mass Spectrometry What Biotech Licensing Really Buys Beyond Conventional CRISPR Oral Sleep Apnea Therapy Poised to Expand Treatment Options Beyond the Payload Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion Tissue Engineering Takes Shape Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests STAT+: In China, a flood of controversial clinical trials slows to a trickle STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut STAT+: A possible comeback for a failed sickle cell gene therapy STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy Tetraploid Astrocytes Emerge as Potential Players in Drug-Resistant Temporal Lobe Epilepsy Ramaswamy’s biotech baggage haunted his political run From gene editing to RNA therapies: The biotech trends to look out for at AHA Scientific Sessions 2026 The biggest biotech funding rounds in October 2026 Patient Advocacy Coffee Chat: Basic steps to being a good advocate BIO responds to Health Affairs Analysis, highlighting the importance of orphan drug incentives Pfizer eyes Europe first for Lyme vaccine as prevalence rises in US With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave Boehringer bets big on China, offering $7B biobucks for Sino cancer programs 1 in 5 have had multiple biopharma layoffs, poll finds Beyond the needle: The future of intratumoral therapy Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca T-time: British biotech pours $133M into the pot for bispecifics Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma Boehringer forges $7bn alliance with China’s SBP Group UK biotechs T-Therapeutics and Alethio score big financings Bayer’s Hyrnuo moves first-line for lung cancer in China Linking kinase inhibitors for greater selectivity Checkpoint inhibitor combinations: the trial-to-approval gap Degraders take on GPCRs STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill Novartis subsidiary Avidity will lay off 40 in San Diego Home